Search

Your search keyword '"den Hollander, Jan G"' showing total 129 results
Start Over Author "den Hollander, Jan G"
129 results on '"den Hollander, Jan G"'

1. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Author

Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, Inciarte Portillo, Alexy, Cahn, Pedro, Lombaard, Johannes, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, and Lahoulou, Rima

Published
2024
Full Text
View/download PDF

4. Development and validation of an early warning model for hospitalized COVID-19 patients: a multi-center retrospective cohort study

Author

Smit, Jim M., Krijthe, Jesse H., Tintu, Andrei N., Endeman, Henrik, Ludikhuize, Jeroen, van Genderen, Michel E., Hassan, Shermarke, El Moussaoui, Rachida, Westerweel, Peter E., Goekoop, Robbert J., Waverijn, Geeke, Verheijen, Tim, den Hollander, Jan G., de Boer, Mark G. J., Gommers, Diederik A. M. P. J., van der Vlies, Robin, Schellings, Mark, Carels, Regina A., van Nieuwkoop, Cees, Arbous, Sesmu M., van Bommel, Jasper, Knevel, Rachel, de Rijke, Yolanda B., and Reinders, Marcel J. T.

Published
2022
Full Text
View/download PDF

6. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study

Author

Vasylyev, Marta, primary, Wit, Ferdinand W N M, additional, Jordans, Carlijn C E, additional, Soetekouw, Robin, additional, van Lelyveld, Steven F L, additional, Kootstra, Gert-Jan, additional, Delsing, Corine E, additional, Ammerlaan, Heidi S M, additional, van Kasteren, Marjo E E, additional, Brouwer, Annemarie E, additional, Leyten, Eliane M S, additional, Claassen, Mark A A, additional, Hassing, Robert-Jan, additional, den Hollander, Jan G, additional, van den Berge, Marcel, additional, Roukens, Anna H E, additional, Bierman, Wouter F W, additional, Groeneveld, Paul H P, additional, Lowe, Selwyn H, additional, van Welzen, Berend J, additional, Richel, Olivier, additional, Nellen, Jeannine F, additional, van den Berk, Guido E L, additional, van der Valk, Marc, additional, Rijnders, Bart J A, additional, and Rokx, Casper, additional

Published
2024
Full Text
View/download PDF

7. Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

Author

Hensley, Kathryn S., Jongkees, Marlou J., Geers, Daryl, GeurtsvanKessel, Corine H., Mueller, Yvonne M., Dalm, Virgil A. S. H., Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G., Bierman, Wouter F. W., Gelinck, Luc B. S., Schippers, Emile F., Ammerlaan, Heidi S. M., van der Valk, Marc, van Vonderen, Marit G. A., Delsing, Corine E., Gisolf, Elisabeth H., Bruns, Anke H. W., Lauw, Fanny N., Berrevoets, Marvin A. H., Sigaloff, Kim C. E., Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J. J., Lowe, Selwyn H., de Vries, Rory D., Katsikis, Peter D., Rijnders, Bart J. A., Brinkman, Kees, Roukens, Anna H. E., and Rokx, Casper

Subjects
Biological sciences
Abstract

Author(s): Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, Corine H. GeurtsvanKessel, Yvonne M. Mueller, Virgil A. S. H. Dalm, Grigorios Papageorgiou, Hanka Steggink, Alicja Gorska, Susanne Bogers, Jan G. [...]

Published
2023
Full Text
View/download PDF

8. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus:DUALING Prospective Nationwide Matched Cohort Study

Author

Vasylyev, Marta, Wit, Ferdinand W.N.M., Jordans, Carlijn C.E., Soetekouw, Robin, van Lelyveld, Steven F.L., Kootstra, Gert Jan, Delsing, Corine E., Ammerlaan, Heidi S.M., van Kasteren, Marjo E.E., Brouwer, Annemarie E., Leyten, Eliane M.S., Claassen, Mark A.A., Hassing, Robert Jan, den Hollander, Jan G., van den Berge, Marcel, Roukens, Anna H.E., Bierman, Wouter F.W., Groeneveld, Paul H.P., Lowe, Selwyn H., van Welzen, Berend J., Richel, Olivier, Nellen, Jeannine F., van den Berk, Guido E.L., van der Valk, Marc, Rijnders, Bart J.A., Rokx, Casper, Vasylyev, Marta, Wit, Ferdinand W.N.M., Jordans, Carlijn C.E., Soetekouw, Robin, van Lelyveld, Steven F.L., Kootstra, Gert Jan, Delsing, Corine E., Ammerlaan, Heidi S.M., van Kasteren, Marjo E.E., Brouwer, Annemarie E., Leyten, Eliane M.S., Claassen, Mark A.A., Hassing, Robert Jan, den Hollander, Jan G., van den Berge, Marcel, Roukens, Anna H.E., Bierman, Wouter F.W., Groeneveld, Paul H.P., Lowe, Selwyn H., van Welzen, Berend J., Richel, Olivier, Nellen, Jeannine F., van den Berk, Guido E.L., van der Valk, Marc, Rijnders, Bart J.A., and Rokx, Casper

Abstract

Background. Confirming the efficacy of dolutegravir/lamivudine in clinical practice solidifies recommendations on its use. Methods. Prospective cohort study (DUALING) in 24 human immunodeficiency virus (HIV) treatment centers in the Netherlands. HIV RNA–suppressed cases were on triple-drug antiretroviral regimens without prior virological failure or resistance and started dolutegravir/lamivudine. Cases were 1:2 matched to controls on triple-drug antiretroviral regimens by the use of dolutegravir-based regimens, age, sex, transmission route, CD4+ T-cell nadir, and HIV RNA zenith. The primary endpoint was the treatment failure rate in cases versus controls at 1 year by intention-to-treat and on-treatment analyses with 5% noninferiority margin. Results. The 2040 participants were 680 cases and 1380 controls. Treatment failure in the 390 dolutegravir-based cases versus controls occurred in 8.72% and 12.50% (difference: −3.78% [95% confidence interval {CI}, −7.49% to .08%]) by intention-to-treat and 1.39% and 0.80% (difference: 0.59% [95% CI, –.80% to 1.98%]) by on-treatment analyses. The treatment failure risk in 290 non-dolutegravir-based cases was also noninferior to controls. Antiretroviral regimen modifications unrelated to virological failure explained the higher treatment failure rate by intention-to-treat. A shorter time on triple-drug antiretroviral therapy and being of non-Western origin was associated with treatment failure. Treatment failure, defined as 2 consecutive HIV RNA >50 copies/mL, occurred in 4 cases and 5 controls but without genotypic resistance detected. Viral blips occured comparable in cases and controls but cases gained more weight, especially when tenofovir-based regimens were discontinued. Conclusions. In routine care, dolutegravir/lamivudine was noninferior to continuing triple-drug antiretroviral regimens after 1 year, supporting the use of dolutegravir/lamivudine in clinical practice.

Published
2024

9. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Author

Gharbharan, Arvind, Jordans, Carlijn C. E., GeurtsvanKessel, Corine, den Hollander, Jan G., Karim, Faiz, Mollema, Femke P. N., Stalenhoef – Schukken, Janneke E., Dofferhoff, Anthonius, Ludwig, Inge, Koster, Adrianus, Hassing, Robert-Jan, Bos, Jeannet C., van Pottelberge, Geert R., Vlasveld, Imro N., Ammerlaan, Heidi S. M., van Leeuwen – Segarceanu, Elena M., Miedema, Jelle, van der Eerden, Menno, Schrama, Thijs J., Papageorgiou, Grigorios, te Boekhorst, Peter, Swaneveld, Francis H., Mueller, Yvonne M., Schreurs, Marco W. J., van Kampen, Jeroen J. A., Rockx, Barry, Okba, Nisreen M. A., Katsikis, Peter D., Koopmans, Marion P. G., Haagmans, Bart L., Rokx, Casper, and Rijnders, Bart J. A.

Published
2021
Full Text
View/download PDF

10. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

Author

Hensley, Kathryn S., Jongkees, Marlou J., Geers, Daryl, GeurtsvanKessel, Corine H., Mueller, Yvonne M., Dalm, Virgil A. S. H., Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G., Bierman, Wouter F. W., Gelinck, Luc B. S., Schippers, Emile F., Ammerlaan, Heidi S. M., van der Valk, Marc, van Vonderen, Marit G. A., Delsing, Corine E., Gisolf, Elisabeth H., Bruns, Anke H. W., Lauw, Fanny N., Berrevoets, Marvin A. H., Sigaloff, Kim C. E., Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J. J., Lowe, Selwyn H., de Vries, Rory D., Katsikis, Peter D., Rijnders, Bart J. A., Brinkman, Kees, Roukens, Anna H. E., and Rokx, Casper

Subjects
Immune response -- Evaluation -- Comparative analysis, HIV patients -- Drug therapy, Biological sciences
Abstract

Background Vaccines can be less immunogenic in people living with HIV (PLWH), but for SARS-CoV-2 vaccinations this is unknown. In this study we set out to investigate, for the vaccines currently approved in the Netherlands, the immunogenicity and reactogenicity of SARS-CoV-2 vaccinations in PLWH. Methods and findings We conducted a prospective cohort study to examine the immunogenicity of BNT162b2, mRNA-1273, ChAdOx1-S, and Ad26.COV2.S vaccines in adult PLWH without prior COVID-19, and compared to HIV-negative controls. The primary endpoint was the anti-spike SARS-CoV-2 IgG response after mRNA vaccination. Secondary endpoints included the serological response after vector vaccination, anti-SARS-CoV-2 T-cell response, and reactogenicity. Between 14 February and 7 September 2021, 1,154 PLWH (median age 53 [IQR 44-60] years, 85.5% male) and 440 controls (median age 43 [IQR 33-53] years, 28.6% male) were included in the final analysis. Of the PLWH, 884 received BNT162b2, 100 received mRNA-1273, 150 received ChAdOx1-S, and 20 received Ad26.COV2.S. In the group of PLWH, 99% were on antiretroviral therapy, 97.7% were virally suppressed, and the median CD4+ T-cell count was 710 cells/[mu]L (IQR 520-913). Of the controls, 247 received mRNA-1273, 94 received BNT162b2, 26 received ChAdOx1-S, and 73 received Ad26.COV2.S. After mRNA vaccination, geometric mean antibody concentration was 1,418 BAU/mL in PLWH (95% CI 1322-1523), and after adjustment for age, sex, and vaccine type, HIV status remained associated with a decreased response (0.607, 95% CI 0.508-0.725, p 300 BAU/mL, whilst in PLWH this response rate was 93.6%. In PLWH vaccinated with mRNA-based vaccines, higher antibody responses were predicted by CD4+ T-cell count 250-500 cells/[mu]L (2.845, 95% CI 1.876-4.314, p 500 cells/[mu]L (2.936, 95% CI 1.961-4.394, p 50 copies/mL was associated with a reduced response (0.454, 95% CI 0.286-0.720, p = 0.001). Increased IFN-[gamma], CD4+ T-cell, and CD8+ T-cell responses were observed after stimulation with SARS-CoV-2 spike peptides in ELISpot and activation-induced marker assays, comparable to controls. Reactogenicity was generally mild, without vaccine-related serious adverse events. Due to the control of vaccine provision by the Dutch National Institute for Public Health and the Environment, there were some differences between vaccine groups in the age, sex, and CD4+ T-cell counts of recipients. Conclusions After vaccination with BNT162b2 or mRNA-1273, anti-spike SARS-CoV-2 antibody levels were reduced in PLWH compared to HIV-negative controls. To reach and maintain the same serological responses as HIV-negative controls, additional vaccinations are probably required. Trial registration The trial was registered in the Netherlands Trial Register (NL9214). https://www.trialregister.nl/trial/9214., Author(s): Kathryn S. Hensley 1, Marlou J. Jongkees 1, Daryl Geers 2, Corine H. GeurtsvanKessel 2, Yvonne M. Mueller 3, Virgil A. S. H. Dalm 3,4, Grigorios Papageorgiou 5, Hanka [...]

Published
2022
Full Text
View/download PDF

12. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Author

Orkin, Chloe, Molina, Jean-Michel, Cahn, Pedro, Lombaard, Johannes, Supparatpinyo, Khuanchai, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, Lahoulou, Rima, Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, and Inciarte Portillo, Alexy

Abstract

In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and efavirenz through to 48 and 96 weeks. Here we report 192-week results from both studies.

Published
2024
Full Text
View/download PDF

13. The roles of the general practitioner and sexual health centre in HIV testing:comparative insights and impact on HIV incidence rates in the Rotterdam area, the Netherlands - a cross-sectional population-based study

Author

Twisk, Denise E., Meima, Abraham, Richardus, Jan Hendrik, van Sighem, Ard, Rokx, Casper, den Hollander, Jan G., Götz, Hannelore M., Twisk, Denise E., Meima, Abraham, Richardus, Jan Hendrik, van Sighem, Ard, Rokx, Casper, den Hollander, Jan G., and Götz, Hannelore M.

Abstract

Background: Access to HIV testing is crucial for detection, linkage to treatment, and prevention. In less urbanised areas, reliance on general practitioners (GPs) for HIV testing is probable, as sexual health centres (SHC) are mostly located within urbanised areas. Limited insight into individuals undergoing HIV testing stems from sparse standard registration of demographics at GPs. This cross-sectional study aims (1) to assess and compare HIV testing at the GP and SHC, and (2) to assess population- and provider-specific HIV incidence. Methods: Individual HIV testing data of GPs and SHC were linked to population register data (aged ≥ 15 years, Rotterdam area, 2015–2019). We reported the proportion HIV tested, and compared GP and SHC testing rates with negative binomial generalised additive models. Data on new HIV diagnoses (2015–2019) from the Dutch HIV Monitoring Foundation relative to the population were used to assess HIV incidence. Results: The overall proportion HIV tested was 1.14% for all residents, ranging from 0.41% for ≥ 40-year-olds to 4.70% for Antilleans. The GP testing rate was generally higher than the SHC testing rate with an overall rate ratio (RR) of 1.61 (95% CI: 1.56–1.65), but not for 15-24-year-olds (RR: 0.81, 95% CI: 0.74–0.88). Large differences in HIV testing rate (1.36 to 39.47 per 1,000 residents) and GP-SHC ratio (RR: 0.23 to 7.24) by geographical area were observed. The GPs’ contribution in HIV testing was greater for GP in areas further away from the SHC. In general, population groups that are relatively often tested are also the groups with most diagnoses and highest incidence (e.g., men who have sex with men, non-western). The overall incidence was 10.55 per 100,000 residents, varying from 3.09 for heterosexual men/women to 24.04 for 25–29-year-olds. Conclusions: GPs have a pivotal role in HIV testing in less urbanised areas further away from the SHC, and among some population groups. A relatively high incidence often follows relat

Published
2023

14. Outcomes of Bariatric Surgery in People With Human Immunodeficiency Virus:A Retrospective Analysis From the ATHENA Cohort

Author

Zino, Leena, Wit, Ferdinand, Rokx, Casper, Den Hollander, Jan G., Van Der Valk, Mark, Richel, Olivier, Burger, David M., Colbers, Angela, Zino, Leena, Wit, Ferdinand, Rokx, Casper, Den Hollander, Jan G., Van Der Valk, Mark, Richel, Olivier, Burger, David M., and Colbers, Angela

Abstract

Background: The implications of bariatric surgery (BS) on virologic and metabolic outcomes in people with human immunodeficiency virus (HIV; PWH) on antiretroviral therapy (ART) are unknown. Methods: Here, we report a retrospective analysis up to 18 months post-BS in PWH from the AIDS Therapy evaluation in The Netherlands (ATHENA) cohort with data from all dutch HIV treating Centers. Primary end points were a confirmed virologic failure (2 consecutive HIV-RNA measurements >200 copies/mL) and the percentage of patients who achieved >20% total body weight loss up to 18 months post-BS. Switches from baseline ART and trough plasma concentrations of antiretrovirals were also reported post-BS. Metabolic parameters and medication usage were compared pre- and post-BS. Results: Fifty-one patients were included. One case of confirmed virologic failure and 3 cases with viral blips were detected in this cohort up to 18 months post-BS. Eighty-five percent of patients achieved >20% total body weight loss at 18 months post-BS, with a mean difference from baseline (95% confidence interval) of -33.5% (-37.7% to -29.3%). Trough plasma concentrations of measured antiretroviral agents were all above minimum effective concentrations, except for 1 sample of darunavir. Lipid profiles, but not serum creatinine and blood pressure, improved significantly (P <. 01) post-BS. Total medications and obesity-related comedications declined from 203 to 103 and from 62 to 25, respectively, at 18 months post-BS. Conclusions: BS was an effective intervention for weight loss and lipid control in PWH using ART in this cohort with no clear link to poor virologic outcomes.

Published
2023

15. Patients treated with rituximab are poorly screened for hepatitis B infection:Data from a low-incidence country

Author

Brakenhoff, Sylvia M., Hoekstra, Roos, Honkoop, Pieter, Roomer, Robert, den Hollander, Jan G., Bezemer, Geert, de Knegt, Robert J., Sonneveld, Milan J., de Man, Robert A., Brakenhoff, Sylvia M., Hoekstra, Roos, Honkoop, Pieter, Roomer, Robert, den Hollander, Jan G., Bezemer, Geert, de Knegt, Robert J., Sonneveld, Milan J., and de Man, Robert A.

Abstract

Background & Aims: Patients with chronic or resolved hepatitis B are at risk of hepatitis B reactivation (HBVr) when treated with high-risk immunosuppressive therapy such as rituximab. Therefore, international guidelines recommend HBV screening prior to rituximab treatment and subsequent antiviral prophylaxis among patients with a (resolved) infection. In this study, we evaluated the adherence to those recommendations. Methods: This is a retrospective multicentre study including patients treated with rituximab between 2000-2021. Performance of correct screening was assessed, defined as the measurement of hepatitis B surface antigen (HBsAg) and hepatitis B core antibodies (anti-HBc). Next, initiation of antiviral prophylaxis and HBVr rate among patients with a chronic or resolved HBV infection was studied. Results: We enrolled 3,176 patients of whom 1,448 (46%) were screened correctly. Screening rates differed significantly between academic and non-academic hospitals; respectively 65% vs 32% (p<0.001). In addition, screening rates differed across specialties and improved throughout the years; from 32% before 2012 to 75% after 2020 among academic prescribers, versus 1% to 60% among non-academic prescribers (both p<0.001). Antiviral prophylaxis was initiated in 58% vs 36% of the patients with a chronic or resolved HBV infection. Seven patients experienced HBVr, including one fatal liver decompensation. Conclusions: Many patients treated with rituximab were not correctly screened for HBV infection and antiviral prophylaxis was often not initiated. Although screening rates improved over time, rates remain suboptimal. With the increasing number of indications for rituximab and other immunosuppressive agents these findings could raise awareness among all medical specialties prescribing these agents.

Published
2023

16. Socio‐economic factors associated with loss to follow‐up among individuals with HCV: A Dutch nationwide cross‐sectional study.

Author

van Dijk, Marleen, Boyd, Anders, Brakenhoff, Sylvia M., Isfordink, Cas J., van Zoest, Rosan A., Verhagen, Mark D., de Knegt, Robert J., Drenth, Joost P. H., van der Valk, Marc, van Wijngaarden, Peter, Douma, Renée A., Erkelens, Willemien G., Lammers, Adriana J. J., de Jonge, Hendrik J. M., Bus, Paul J., den Hollander, Jan G., Posthouwer, Dirk, Klemt‐Kropp, Michael, and Baak, Lubbertus C.

Subjects
SOCIOECONOMIC factors, INCOME, HEPATITIS C virus, CROSS-sectional method, DEATH rate
Abstract

Background and Aims: The path to hepatitis C virus (HCV) elimination is complicated by individuals who become lost to follow‐up (LTFU) during care, particularly before receiving effective HCV treatment. We aimed to determine factors contributing to LTFU and whether LTFU is associated with mortality. Methods: In this secondary analysis, we constructed a database including individuals with HCV who were either LTFU (data from the nationwide HCV retrieval project, CELINE) or treated with directly acting antivirals (DAA) (data from Statistics Netherlands) between 2012 and 2019. This database was linked to mortality data from Statistics Netherlands. Determinants associated with being LTFU versus DAA‐treated were assessed using logistic regression, and mortality rates were compared between groups using exponential survival models. These analyses were additionally stratified on calendar periods: 2012–2014, 2015–2017 and 2018–2019. Results: About 254 individuals, LTFU and 5547 DAA‐treated were included. Being institutionalized (OR = 5.02, 95% confidence interval (CI) = 3.29–7.65), household income below the social minimum (OR = 1.96, 95% CI = 1.25–3.06), receiving benefits (OR = 1.74, 95% CI = 1.20–2.52) and psychiatric comorbidity (OR = 1.51, 95% CI = 1.09–2.10) were associated with LTFU. Mortality rates were significantly higher in individuals LTFU compared to those DAA‐treated (2.99 vs. 1.15/100 person‐years (PY), p <.0001), while in those DAA‐treated, mortality rates slowly increased between 2012–2014 (.22/100PY) and 2018–2019 (2.25/100PY). Conclusion: In the Netherlands, individuals who are incarcerated/institutionalized, with low household income, or with psychiatric comorbidities are prone to being LTFU, which is associated with higher mortality. HCV care needs to be adapted for these vulnerable individuals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Erratum: Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study (PLoS medicine (2022) 19 10 (e1003979))

Author

Hensley, Kathryn S., Jongkees, Marlou J., Geers, Daryl, GeurtsvanKessel, Corine H., Mueller, Yvonne M., Dalm, Virgil A. S. H., Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G., Bierman, Wouter F. W., Gelinck, Luc B. S., Schippers, Emile F., Ammerlaan, Heidi S. M., van der Valk, Marc, van Vonderen, Marit G. A., Delsing, Corine E., Gisolf, Elisabeth H., Bruns, Anke H. W., Lauw, Fanny N., Berrevoets, Marvin A. H., Sigaloff, Kim C. E., Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J. J., Lowe, Selwyn H., de Vries, Rory D., Katsikis, Peter D., Rijnders, Bart J. A., Brinkman, Kees, Roukens, Anna H. E., Rokx, Casper, Infectious diseases, and AII - Infectious diseases

Abstract

[This corrects the article DOI: 10.1371/journal.pmed.1003979.].

Published
2023

18. Erratum:Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study (PLoS Med (2022) 19:10 (e1003979) DOI: 10.1371/journal.pmed.1003979)

Author

Hensley, Kathryn S., Jongkees, Marlou J., Geers, Daryl, GeurtsvanKessel, Corine H., Mueller, Yvonne M., Dalm, Virgil A. S. H., Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G., Bierman, Wouter F. W., Gelinck, Luc B. S., Schippers, Emile F., Ammerlaan, Heidi S. M., van der Valk, Marc, van Vonderen, Marit G. A., Delsing, Corine E., Gisolf, Elisabeth H., Bruns, Anke H. W., Lauw, Fanny N., Berrevoets, Marvin A. H., Sigaloff, Kim C. E., Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J. J., Lowe, Selwyn H., de Vries, Rory D., Katsikis, Peter D., Rijnders, Bart J. A., Brinkman, Kees, Roukens, Anna H. E., Rokx, Casper, and Internal medicine

Abstract

Fig 3 panel B contains a mislabeled axis. The label ‘Pre—HIV negative’ should be ‘Post—HIV negative.’ Please see the correct Fig 3 below.

Published
2023
Full Text
View/download PDF

19. Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination

Author

Jongkees, Marlou J, primary, Geers, Daryl, additional, Hensley, Kathryn S, additional, Huisman, Wesley, additional, GeurtsvanKessel, Corine H, additional, Bogers, Susanne, additional, Gommers, Lennert, additional, Papageorgiou, Grigorios, additional, Jochems, Simon P, additional, den Hollander, Jan G, additional, Schippers, Emile F, additional, Ammerlaan, Heidi S M, additional, Bierman, Wouter F W, additional, van der Valk, Marc, additional, Berrevoets, Marvin A H, additional, Soetekouw, Robert, additional, Langebeek, Nienke, additional, Bruns, Anke H W, additional, Leyten, Eliane M S, additional, Sigaloff, Kim C E, additional, van Vonderen, Marit G A, additional, Delsing, Corine E, additional, Branger, Judith, additional, Katsikis, Peter D, additional, Mueller, Yvonne M, additional, de Vries, Rory D, additional, Rijnders, Bart J A, additional, Brinkman, Kees, additional, Rokx, Casper, additional, and Roukens, Anna H E, additional

Published
2022
Full Text
View/download PDF

20. Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people living with HIV with hyporesponse after primary vaccination

Author

Jongkees, Marlou J., primary, Geers, Daryl, additional, Hensley, Kathryn S., additional, Huisman, Wesley, additional, GeurtsvanKessel, Corine H., additional, Bogers, Susanne, additional, Gommers, Lennert, additional, Papageorgiou, Grigorios, additional, Jochems, Simon P., additional, den Hollander, Jan G., additional, Schippers, Emile F., additional, Ammerlaan, Heidi S.M., additional, Bierman, Wouter F.W., additional, van der Valk, Marc, additional, Berrevoets, Marvin A.H., additional, Soetekouw, Robert, additional, Langebeek, Nienke, additional, Bruns, Anke H.W., additional, Leyten, Eliane M.S., additional, Sigaloff, Kim C.E., additional, van Vonderen, Marit G.A., additional, Delsing, Corine E., additional, Branger, Judith, additional, Katsikis, Peter D., additional, Mueller, Yvonne M., additional, de Vries, Rory D., additional, Rijnders, Bart J.A., additional, Brinkman, Kees, additional, Rokx, Casper, additional, and Roukens, Anna H.E., additional

Published
2022
Full Text
View/download PDF

22. Development and validation of an early warning model for hospitalized COVID-19 patients:a multi-center retrospective cohort study

Author

Smit, Jim M., Krijthe, Jesse H., Tintu, Andrei N., Endeman, Henrik, Ludikhuize, Jeroen, van Genderen, Michel E., Hassan, Shermarke, El Moussaoui, Rachida, Westerweel, Peter E., Goekoop, Robbert J., Waverijn, Geeke, Verheijen, Tim, den Hollander, Jan G., de Boer, Mark G. J., Gommers, Diederik A. M. P. J., van der Vlies, Robin, Schellings, Mark, Carels, Regina A., van Nieuwkoop, Cees, Arbous, Sesmu M., van Bommel, Jasper, Knevel, Rachel, de Rijke, Yolanda B., Reinders, Marcel J. T., Smit, Jim M., Krijthe, Jesse H., Tintu, Andrei N., Endeman, Henrik, Ludikhuize, Jeroen, van Genderen, Michel E., Hassan, Shermarke, El Moussaoui, Rachida, Westerweel, Peter E., Goekoop, Robbert J., Waverijn, Geeke, Verheijen, Tim, den Hollander, Jan G., de Boer, Mark G. J., Gommers, Diederik A. M. P. J., van der Vlies, Robin, Schellings, Mark, Carels, Regina A., van Nieuwkoop, Cees, Arbous, Sesmu M., van Bommel, Jasper, Knevel, Rachel, de Rijke, Yolanda B., and Reinders, Marcel J. T.

Abstract

Background: Timely identification of deteriorating COVID-19 patients is needed to guide changes in clinical management and admission to intensive care units (ICUs). There is significant concern that widely used Early warning scores (EWSs) underestimate illness severity in COVID-19 patients and therefore, we developed an early warning model specifically for COVID-19 patients.Methods: We retrospectively collected electronic medical record data to extract predictors and used these to fit a random forest model. To simulate the situation in which the model would have been developed after the first and implemented during the second COVID-19 `wave' in the Netherlands, we performed a temporal validation by splitting all included patients into groups admitted before and after August 1, 2020. Furthermore, we propose a method for dynamic model updating to retain model performance over time. We evaluated model discrimination and calibration, performed a decision curve analysis, and quantified the importance of predictors using SHapley Additive exPlanations values.Results: We included 3514 COVID-19 patient admissions from six Dutch hospitals between February 2020 and May 2021, and included a total of 18 predictors for model fitting. The model showed a higher discriminative performance in terms of partial area under the receiver operating characteristic curve (0.82 [0.80-0.84]) compared to the National early warning score (0.72 [0.69-0.74]) and the Modified early warning score (0.67 [0.65-0.69]), a greater net benefit over a range of clinically relevant model thresholds, and relatively good calibration (intercept = 0.03 [- 0.09 to 0.14], slope = 0.79 [0.73-0.86]).Conclusions: This study shows the potential benefit of moving from early warning models for the general inpatient population to models for specific patient groups. Further (independent) validation of the model is needed.

Published
2022

23. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

Author

MS Interne Geneeskunde, Infection & Immunity, Hensley, Kathryn S, Jongkees, Marlou J, Geers, Daryl, GeurtsvanKessel, Corine H, Mueller, Yvonne M, Dalm, Virgil A S H, Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G, Bierman, Wouter F W, Gelinck, Luc B S, Schippers, Emile F, Ammerlaan, Heidi S M, van der Valk, Marc, van Vonderen, Marit G A, Delsing, Corine E, Gisolf, Elisabeth H, Bruns, Anke H W, Lauw, Fanny N, Berrevoets, Marvin A H, Sigaloff, Kim C E, Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J J, Lowe, Selwyn H, de Vries, Rory D, Katsikis, Peter D, Rijnders, Bart J A, Brinkman, Kees, Roukens, Anna H E, Rokx, Casper, MS Interne Geneeskunde, Infection & Immunity, Hensley, Kathryn S, Jongkees, Marlou J, Geers, Daryl, GeurtsvanKessel, Corine H, Mueller, Yvonne M, Dalm, Virgil A S H, Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G, Bierman, Wouter F W, Gelinck, Luc B S, Schippers, Emile F, Ammerlaan, Heidi S M, van der Valk, Marc, van Vonderen, Marit G A, Delsing, Corine E, Gisolf, Elisabeth H, Bruns, Anke H W, Lauw, Fanny N, Berrevoets, Marvin A H, Sigaloff, Kim C E, Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J J, Lowe, Selwyn H, de Vries, Rory D, Katsikis, Peter D, Rijnders, Bart J A, Brinkman, Kees, Roukens, Anna H E, and Rokx, Casper

Published
2022

24. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV: a nationwide prospective cohort study in the Netherlands

Author

Hensley, Kathryn S., primary, Jongkees, Marlou J., additional, Geers, Daryl, additional, GeurtsvanKessel, Corine H., additional, Mueller, Yvonne M., additional, Dalm, Virgil A.S.H., additional, Papageorgiou, Grigorios, additional, Steggink, Hanka, additional, Gorska, Alicja, additional, Bogers, Susanne, additional, den Hollander, Jan G., additional, Bierman, Wouter F.W., additional, Gelinck, Luc B.S., additional, Schippers, Emile F., additional, Ammerlaan, Heidi S.M., additional, van der Valk, Marc, additional, van Vonderen, Marit G.A., additional, Delsing, Corine E., additional, Gisolf, Elisabeth H., additional, Bruns, Anke H.W., additional, Lauw, Fanny N., additional, Berrevoets, Marvin A.H., additional, Sigaloff, Kim C.E., additional, Soetekouw, Robert, additional, Branger, Judith, additional, de Mast, Quirijn, additional, Lammers, Adriana J.J., additional, Lowe, Selwyn H., additional, de Vries, Rory D., additional, Katsikis, Peter D., additional, Rijnders, Bart J.A., additional, Brinkman, Kees, additional, Roukens, Anna H.E., additional, and Rokx, Casper, additional

Published
2022
Full Text
View/download PDF

25. Additional file 1 of Development and validation of an early warning model for hospitalized COVID-19 patients: a multi-center retrospective cohort study

Author

Smit, Jim M., Krijthe, Jesse H., Tintu, Andrei N., Endeman, Henrik, Ludikhuize, Jeroen, van Genderen, Michel E., Hassan, Shermarke, El Moussaoui, Rachida, Westerweel, Peter E., Goekoop, Robbert J., Waverijn, Geeke, Verheijen, Tim, den Hollander, Jan G., de Boer, Mark G. J., Gommers, Diederik A. M. P. J., van der Vlies, Robin, Schellings, Mark, Carels, Regina A., van Nieuwkoop, Cees, Arbous, Sesmu M., van Bommel, Jasper, Knevel, Rachel, de Rijke, Yolanda B., and Reinders, Marcel J. T.

Abstract

Additional file 1. Appendices.

Published
2022
Full Text
View/download PDF

27. Convalescent Plasma for COVID-19. A randomized clinical trial

Author

Gharbharan, Arvind, primary, Jordans, Carlijn C.E., additional, Geurtsvankessel, Corinne, additional, den Hollander, Jan G., additional, Karim, Faiz, additional, Mollema, Femke P. N., additional, Stalenhoef-Schukken, Janneke E., additional, Dofferhoff, Anthonius, additional, Ludwig, Inge, additional, Koster, Adrianus, additional, Hassing, Robert-Jan, additional, Bos, Jeannet C., additional, van Pottelberge, Geert R., additional, Vlasveld, Imro N., additional, Ammerlaan, Heidi S. M., additional, van Leeuwen-Segarceanu, Elena M., additional, Miedema, Jelle, additional, van der Eerden, Menno, additional, Papageorgiou, Grigorios, additional, Boekhorst, Peter te, additional, Swaneveld, Francis H., additional, Katsikis, Peter D., additional, Mueller, Yvonne, additional, Okba, Nisreen M.A., additional, Koopmans, Marion P.G., additional, Haagmans, Bart H.G., additional, Rokx, Casper, additional, and Rijnders, Bart J.A., additional

Published
2020
Full Text
View/download PDF

37. Within-Host and Population Transmission of blaOXA-48 in K. pneumoniae and E. coli

Author

Haverkate, Manon R, Dautzenberg, Mirjam J D, Ossewaarde, Tjaco J M, van der Zee, Anneke, den Hollander, Jan G, Troelstra, Annet, Bonten, Marc J M, Bootsma, Martin C J, Sub Mathematical Modeling, Mathematical Modeling, Sub Mathematical Modeling, and Mathematical Modeling

Subjects
Imipenem, Gene Transfer, Horizontal, Klebsiella pneumoniae, medicine.drug_class, Population, Antibiotics, lcsh:Medicine, Drug resistance, Research Support, medicine.disease_cause, Meropenem, beta-Lactamases, Microbiology, Antibiotic resistance, Drug Resistance, Bacterial, polycyclic compounds, Escherichia coli, medicine, Journal Article, Humans, Non-U.S. Gov't, lcsh:Science, education, Escherichia coli Infections, education.field_of_study, Multidisciplinary, integumentary system, biology, Escherichia coli Proteins, Research Support, Non-U.S. Gov't, lcsh:R, biochemical phenomena, metabolism, and nutrition, biology.organism_classification, Klebsiella Infections, 3. Good health, bacteria, lcsh:Q, Research Article, medicine.drug
Abstract

During a large hospital outbreak of OXA-48 producing bacteria, most K. pneumoniae OXA-48 isolates were phenotypically resistant to meropenem or imipenem, whereas most E. coli OXA-48 isolates were phenotypically susceptible to these antibiotics. In the absence of molecular gene-detection E. coli OXA-48 could remain undetected, facilitating cross-transmission and horizontal gene transfer of bla OXA-48. Based on 868 longitudinal molecular microbiological screening results from patients carrying K. pneumoniae OXA-48 (n = 24), E. coli OXA-48 (n = 17), or both (n = 40) and mathematical modelling we determined mean durations of colonisation (278 and 225 days for K. pneumoniae OXA-48 and E. coli OXA-48, respectively), and horizontal gene transfer rates (0.0091/day from K. pneumoniae to E. coli and 0.0015/day vice versa). Based on these findings the maximum effect of horizontal gene transfer of bla OXA-48 originating from E. coli OXA-48 on the basic reproduction number (R 0) is 1.9%, and it is, therefore, unlikely that phenotypically susceptible E. coli OXA-48 will contribute significantly to the spread of bla OXA-48.

Published
2015

38. Within-Host and Population Transmission of blaOXA-48 in K. pneumoniae and E. coli

Author

Sub Mathematical Modeling, Mathematical Modeling, Haverkate, Manon R, Dautzenberg, Mirjam J D, Ossewaarde, Tjaco J M, van der Zee, Anneke, den Hollander, Jan G, Troelstra, Annet, Bonten, Marc J M, Bootsma, Martin C J, Sub Mathematical Modeling, Mathematical Modeling, Haverkate, Manon R, Dautzenberg, Mirjam J D, Ossewaarde, Tjaco J M, van der Zee, Anneke, den Hollander, Jan G, Troelstra, Annet, Bonten, Marc J M, and Bootsma, Martin C J

Published
2015

39. Within-Host and Population Transmission of blaOXA-48 in K. pneumoniae and E. coli

Author

Epi Infectieziekten, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten Team 1, Haverkate, Manon R, Dautzenberg, Mirjam J D, Ossewaarde, Tjaco J M, van der Zee, Anneke, den Hollander, Jan G, Troelstra, Annet, Bonten, Marc J M, Bootsma, Martin C J, Epi Infectieziekten, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten Team 1, Haverkate, Manon R, Dautzenberg, Mirjam J D, Ossewaarde, Tjaco J M, van der Zee, Anneke, den Hollander, Jan G, Troelstra, Annet, Bonten, Marc J M, and Bootsma, Martin C J

Published
2015

43. Within-Host and Population Transmission of blaOXA-48 in K. pneumoniae and E. coli.

Author

Haverkate, Manon R., Dautzenberg, Mirjam J. D., Ossewaarde, Tjaco J. M., van der Zee, Anneke, den Hollander, Jan G., Troelstra, Annet, Bonten, Marc J. M., and Bootsma, Martin C. J.

Subjects
PNEUMONIA, ESCHERICHIA coli diseases, EPIDEMICS, HOSPITAL patients, IMIPENEM, DISEASE susceptibility, INFECTIOUS disease transmission, THERAPEUTICS
Abstract

During a large hospital outbreak of OXA-48 producing bacteria, most K. pneumoniaeOXA-48 isolates were phenotypically resistant to meropenem or imipenem, whereas most E. coliOXA-48 isolates were phenotypically susceptible to these antibiotics. In the absence of molecular gene-detection E. coliOXA-48 could remain undetected, facilitating cross-transmission and horizontal gene transfer of blaOXA-48. Based on 868 longitudinal molecular microbiological screening results from patients carrying K. pneumoniaeOXA-48 (n = 24), E. coliOXA-48 (n = 17), or both (n = 40) and mathematical modelling we determined mean durations of colonisation (278 and 225 days for K. pneumoniaeOXA-48 and E. coliOXA-48, respectively), and horizontal gene transfer rates (0.0091/day from K. pneumoniae to E. coli and 0.0015/day vice versa). Based on these findings the maximum effect of horizontal gene transfer of blaOXA-48 originating from E. coliOXA-48 on the basic reproduction number (R0) is 1.9%, and it is, therefore, unlikely that phenotypically susceptible E. coliOXA-48 will contribute significantly to the spread of blaOXA-48. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results